Moreover, inhibitors of PCSK9, designed to regulate hyperlipidemia by impacting LDL absorption and elimination in liver cells, have been effective in managing the hyperlipidemia linked with nephrotic syndrome [47]. This evidence concerns the gene PCSK9 and hyperlipidemia.